{"id":48755,"date":"2022-09-23T17:02:20","date_gmt":"2022-09-23T15:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/u-s-503b-compounding-pharmacies-market-report-2022-featuring-central-admixture-quva-pharma-fagron-atlas-others-researchandmarkets-com\/"},"modified":"2022-09-23T17:02:20","modified_gmt":"2022-09-23T15:02:20","slug":"u-s-503b-compounding-pharmacies-market-report-2022-featuring-central-admixture-quva-pharma-fagron-atlas-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/u-s-503b-compounding-pharmacies-market-report-2022-featuring-central-admixture-quva-pharma-fagron-atlas-others-researchandmarkets-com\/","title":{"rendered":"U.S. 503B Compounding Pharmacies Market Report 2022: Featuring Central Admixture, QuVa Pharma, Fagron, Atlas & Others – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “U.S. 503B Compounding Pharmacies Market, by Molecule, by Packaging Type – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThese are specialized types of drug manufacturing organizations that serve a critical role in the patient care, as stated by the United States Pharmacopoeia (USP), compounding provides access to medication for patients who may not be able to use commercially available formulations due to dosing requirements, allergies, or rare diseases. The 503B compounding pharmacies are required to be registered with the U.S. FDA and maintain full compliance with the current good manufacturing practices (cGMP).\n<\/p>\n

\nThe cGMP guidelines compounding pharmacies needs to follow are 503B compounding pharmacies are must validate every process according to CGMP.\n<\/p>\n

\n503B facilities must produce multiple batches and submit them for testing and stability before a new product can be brought to market.\n<\/p>\n

\n503B products and testing methods must be validated according to US pharmacopeia (USP). Similarly, all suppliers and vendors providing raw materials must be evaluated. Moreover, onsite inspection must be performed by quality personnel.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nThe increasing launches of 503B compounding pharmacies in the U.S and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the U.S. 503B compounding pharmacies market over the forecast period.\n<\/p>\n

\nFor instance, in January 2022, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced the launch of Hikma 503B, a new outsourced sterile compounding business focused on providing high quality, ready to administer injectable medications that are customized to the specific need of patients in the U.S.\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n